“A positive trend in overall survival” had been seen in a trial, with an interim analysis demonstrating a 29% reduction in the risk of death for Nubeqa. More: Nubeqa success in Phase III prostate cancer study Source: News
read moreLast September, the EMA’s Pharmacovigilance Risk Assessment Committee announced a review of data on skin cancer in patients using the drug. More: LEO issues Picato recall Source: News
read moreThe ruling harks back to the CMA’s 2016 case that found GlaxoSmithKline had agreed to make payments totalling over £50 million to other generic suppliers of paroxetine. More: GSK hit with EU Court ruling over ‘pay-for-delay’ drug case Source: News
read moreThere are currently no approved immunotherapies for the treatment of peanut allergies. More: Peanut allergy vaccine shows promise Source: News
read moreAmgen finished 2019 with another dip in sales thanks to generic and biosimilar challenges to some of its top meds, including blockbuster Neulasta. But for 2020, the drugmaker sees better days ahead thanks to new launches, the recently acquired Otezla and its own biosimilar franchise. More: Copycats
read moreBayer and Orion’s Nubeqa may be late to the prostate cancer market, but new clinical data could give it a better chance at challenging Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Erleada—by making it the first among the three
read more© 1994 - 2026 B.M. Pharmaceuticals